CLINICAL TRIAL / NCT05576077

Key Inclusion Criteria: - Advanced or metastatic breast carcinoma, colorectal adenocarcinoma, uveal melanoma, cutaneous melanoma, non-small cell lung cancer, or head and neck squamous cell carcinoma that has failed or is refractory to standard of care therapy - Have at least one target lesion that can be used for response assessments and have at least 1 tumor amenable for tissue harvest for TIL manufacturing. - ECOG performance status of 0 or 1 - Demonstrate adequate organ function - Additional inclusion criteria exist Key Exclusion Criteria: - Known additional malignancy that is progressing or has required active treatment within the past 3 years - Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy or any other form of immunosuppressive - Currently infected with HIV Type 1 and Type 2, hepatitis B virus (HBV), hepatitis C virus (HCV), treponema pallidum (e.g., syphilis), West Nile virus (WNV), Human T-lymphotropic virus types 1 or II (HTLV I/II), or cytomegalovirus (CMV) - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable - Serious cardiac condition, such as uncontrolled hypertension, concurrent congestive heart failure, prior history of Class III/IV cardiac disease (New York Heart Association [NYHA]), history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment. Patients who are > 60 years of age must undergo cardiology clearance exam and cardiac stress test. - Prior cell therapy or organ transplant - History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, IL-2, or pembrolizumab, or any of their constituents - LVEF ≤ 45% - FEV1 ≤ 60% of predicted value and DLCO (corrected) < 60% of predicted value - Chronic anti-coagulant therapy that cannot either be discontinued or temporarily changed - Additional exclusion criteria exist